
8. juni 2010:Pressemeddelelse nr. 5, 2010: Zealand Pharma Announces An Extension of The Lixisenatide...
The 31st European Peptide Symposium, Copenhagen, Denmark, 5-9 September 2010 (Science) 46th An...
Peptides are signaling molecules comprised of building blocks called amino acids. When the number of amino acids are less than about 50, these molecules are referred to as peptides while longer sequences are referred to as proteins. Peptides selectively interact with specific targets in order to elicit a particular effect.
When compared with small molecule therapies, peptide therapeutics possess certain advantages, including:
Less favorable properties of peptides include:
Zealand Pharma’s Technical Expertise: peptide optimization
Zealand Pharma is focused on designing peptides to minimize the disadvantages of peptide therapeutics while retaining or even enhancing the more favorable characteristics. Zealand Pharma’s core competences and proprietary platform enable the Company to focus on this challenge. Zealand Pharma’s SIP®-technology aims to enable the stabilization of peptides by preventing enzymatic digestion. Consequently, SIP®-modification of a peptide may also enhance the duration of action of a compound. In addition, Zealand Pharma’s experience in synthetic chemistry enables the optimization of peptides with the goal of generating specific qualities, including for example, increased biological half-life and improved product stability.
The wide range of technical opportunities to modify peptides and optimize certain qualities through modeling, design, synthesis and testing provides Zealand Pharma with a base for creating new compounds.
Fill in the form below to tip a friend about this page.
When this page is updated you will be updated by e-mail.
Home Legal Disclaimer Updated: 27.7.2010